Exclusions 
1. HIV or HBsAg positivity. 
2. Women or men of child-bearing age unless a negative pregnancy test 
is obtained prior to enrollment and adequate methods of 
contraception are used during the study period. 
3. Organ dysfunction: 
a. WBC < 3500, or granulocyte count < 1500 
b. Platelets < 100,000 
c. Hemoglobin < 8.0 mg/dl 
d. PT/PTT > 1.2 x upper limit of normal 
e. Creatinine > 2.0 mg/dl 
f. Bilirubin > 1.5 mg/dl 
g. SGOT/SGPT > 2x upper limit of normal, or alkaline 
phosphatase > 4x upper limit of normal. 
h. Albumin < 3.0 mg/dl or CT scan evidence that tumor involves 
greater than 1/3 of the liver parenchyma 
i. Clinical evidence of pulmonary dysfunction (dyspnea at rest 
or with minimal to moderate exertion) . 
j. Significant cardiovascular disease: symptoms of coronary 
artery disease (includes those controlled with medication), 
history of MI , congestive heart failure, chronic 
arrhythmias requiring treatment, peripheral arterial 
insufficiency. 
k. Evidence or history of brain metastases, or seizure 
disorders controlled with medication. 
4. Active infection requiring antibiotics within one week of starting 
therapy. 
5. Requirement for corticosteroids. 
6. Any treatment including radiation therapy for their malignancy 
within 4 weeks of starting treatment (6 weeks for BRM's). 
7. Any medical or psychiatric condition which in the opinion of the 
treating physician or principal investigator would unacceptably 
reduce the safety of the proposed treatment, would impair the 
[732] 
Recombinant DNA Research, Volume 18 
